MA-WASABI-TECHNOLOGIES
9.5.2023 09:01:29 CEST | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, strengthened its foothold in EMEA with the appointment of Jon Howes as Vice President and General Manager for EMEA. Howes will build on Wasabi’s momentous growth in the region, highlighted by a flagship deal with Liverpool Football Club, 1,800 new partners, and a nearly 90% ARR growth rate. Additionally, a full region go-to-market team has been established to support the growth of cloud storage, with Eric Peters as Country Manager of Benelux & Southern Europe based in France; Daniel Arabié, Country Manager of Central Europe/DACH based in Germany, and Kevin Dunn, Country Manager for the UK/I & Nordics based in the UK.
Jon Howes, VP and GM for EMEA, Wasabi Technologies, said:
“Demand for predictably priced, secure, high-performance cloud storage is growing at an unprecedented pace in EMEA, making Wasabi a perfect fit for the market. Our immense traction across Europe is a testament to the value we bring to enterprises and organisations across sports, media and entertainment, surveillance, education, healthcare, and more. Being at the helm of Wasabi’s EMEA operations is a once-in-a-lifetime opportunity, and I look forward to the expansion of Wasabi hot cloud storage in this important region along with our industry-leading team.”
Howes brings more than 20 years’ experience to Wasabi, with deep expertise in scaling go-to-market models for technology companies in EMEA including Juniper Networks, Oracle and Infovista. His initial priorities will be growing Wasabi’s channel presence, scaling its partner and customer base, and strategically increasing Wasabi’s headcount in key European markets, specifically the UK, France and Germany. Meanwhile, Wasabi’s newly appointed country managers hold a plethora of proven sales and channel experience with organisations including AWS, Cloudian, EMC, Juniper Networks, Nimble Storage, and others.
Wasabi’s 'channel-first’ approach in EMEA has established partnerships with Exclusive Networks, Ebertlang, Veeam, Equinix, and more – most recently Skill Partner. Marquee customer wins include Liverpool Football Club, who migrated to Wasabi for predictable, affordable cloud storage without fees for egress or API requests in order to create a central repository for all the club’s digital media.
Drew Crisp, SVP of Digital at Liverpool Football Club, said:
“Many cloud vendors try to be all things to all people, to the customer’s detriment. Wasabi’s singular focus on cloud storage has made them brilliant at what they do. They know the cloud storage space inside and out and have worked with us every step of the way. Not only does Liverpool FC have a very simple cost model with Wasabi as we migrate from on-premises to the cloud, we have price predictability that enables us to truly understand our total cost of ownership, which is essential for us.”
Arnaud Semont, Associate Director at Skill Partner, said:
“Skill Partner goes to market with innovative, disruptive and predictable IT solutions, which is why we partner with Wasabi on our backup and disaster recovery services. We use Wasabi cloud storage to keep an external copy of our customers' data using immutable storage, which ensures data is safe from ransomware with object lock. As a system integrator and service provider based in EMEA, Wasabi's local storage regions help us meet data sovereignty requirements, allowing us to use the Wasabi Paris storage region with replication to Frankfurt.”
Wasabi hot cloud storage is the industry’s most reliable, scalable, and predictably priced cloud storage with no fees for egress or API requests and no vendor lock-in. Wasabi is gaining market traction at a phenomenal pace as organisations globally are looking for cloud storage solutions that fit their budgets and unique needs. It’s also an ideal product for the channel because every organisation needs to store data and Wasabi is simple to understand and integrate with other best-of-breed products. It also offers the highest level of protection in cloud storage with Object Lock immutability and 11 x 9s of data durability. Service launched in EMEA in 2019 with the opening of the Amsterdam storage region. Since then, Wasabi has added storage regions in London, Frankfurt, and Paris to support the company’s rapid growth and to meet customer data sovereignty needs.
Companies in every industry can benefit from Wasabi hot cloud storage and its suite of supporting products and tools like the recently announced Wasabi Surveillance Cloud, which delivers bottomless storage for video surveillance, and a state-of-the-art Carbon Footprint Calculator that helps customers and partners accurately measure and report on their energy use in specific Wasabi data centres as part of their broader ESG objectives.
Regularly named one of technology’s fastest-growing companies, and recognized by analysts as the top alternative to AWS S3, Wasabi has raised over $500 million in funding to support its international expansion and availability for customers of every size. For more information on how Wasabi can partner with your organisation, visit here or contact emeasales@wasabi.com.
About Wasabi Technologies
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organisations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.
Follow and connect with Wasabi on Linkedin,Twitter, Facebook, Instagram, and The Bucket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom